Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
73% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ICPT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ICPT' s 10-Year Cash to Debt Range
Min: 218.39  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.94
ICPT's Equity to Asset is ranked higher than
91% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ICPT: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
ICPT' s 10-Year Equity to Asset Range
Min: -1.08  Med: 0.57 Max: 0.94
Current: 0.94
-1.08
0.94
Interest Coverage No Debt
ICPT's Interest Coverage is ranked lower than
58% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ICPT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ICPT' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 143.70
M-Score: -1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4794.64
ICPT's Operating margin (%) is ranked lower than
88% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ICPT: -4794.64 )
Ranked among companies with meaningful Operating margin (%) only.
ICPT' s 10-Year Operating margin (%) Range
Min: -6496.56  Med: -1602.79 Max: -766.2
Current: -4794.64
-6496.56
-766.2
Net-margin (%) -2754.78
ICPT's Net-margin (%) is ranked lower than
85% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ICPT: -2754.78 )
Ranked among companies with meaningful Net-margin (%) only.
ICPT' s 10-Year Net-margin (%) Range
Min: -16258.67  Med: -2981.90 Max: -705.71
Current: -2754.78
-16258.67
-705.71
ROE (%) -37.39
ICPT's ROE (%) is ranked lower than
56% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ICPT: -37.39 )
Ranked among companies with meaningful ROE (%) only.
ICPT' s 10-Year ROE (%) Range
Min: -180.8  Med: -146.09 Max: -91.41
Current: -37.39
-180.8
-91.41
ROA (%) -27.07
ICPT's ROA (%) is ranked lower than
51% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ICPT: -27.07 )
Ranked among companies with meaningful ROA (%) only.
ICPT' s 10-Year ROA (%) Range
Min: -140.05  Med: -98.58 Max: -51.65
Current: -27.07
-140.05
-51.65
ROC (Joel Greenblatt) (%) -2950.61
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ICPT: -2950.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8893.89  Med: -6278.24 Max: -3008.24
Current: -2950.61
-8893.89
-3008.24
» ICPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ICPT Guru Trades in Q2 2014

Chuck Royce 360 sh (New)
Columbia Wanger 183,300 sh (+37.82%)
Steven Cohen 26,500 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen 208,077 sh (-54.26%)
RS Investment Management 3,214 sh (-91.81%)
Steven Cohen 6,123 sh (-99.51%)
» More
Q3 2014

ICPT Guru Trades in Q3 2014

RS Investment Management 7,016 sh (+118.29%)
Steven Cohen 37,300 sh (+40.75%)
Columbia Wanger 183,300 sh (unchged)
Chuck Royce Sold Out
Andreas Halvorsen Sold Out
» More
Q4 2014

ICPT Guru Trades in Q4 2014

Steven Cohen 300,200 sh (+704.83%)
Columbia Wanger 393,850 sh (+114.87%)
RS Investment Management Sold Out
» More
Q1 2015

ICPT Guru Trades in Q1 2015

Paul Tudor Jones 3,350 sh (New)
Columbia Wanger 315,850 sh (-19.80%)
Steven Cohen 132,300 sh (-55.93%)
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intercept Pharmaceuticals Inc

Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST
According to GuruFocus Insider Data, the largest insider sells during the past week were: Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Target Corp (NYSE:TGT), Aetna Inc (NYSE:AET) and Ross Stores Inc (NASDAQ:ROST). Read more...

Ratios

vs
industry
vs
history
P/B 14.77
ICPT's P/B is ranked lower than
88% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ICPT: 14.77 )
Ranked among companies with meaningful P/B only.
ICPT' s 10-Year P/B Range
Min: 5.27  Med: 14.34 Max: 104.9
Current: 14.77
5.27
104.9
P/S 1980.19
ICPT's P/S is ranked lower than
99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ICPT: 1980.19 )
Ranked among companies with meaningful P/S only.
ICPT' s 10-Year P/S Range
Min: 43.77  Med: 1961.46 Max: 5778.25
Current: 1980.19
43.77
5778.25
EV-to-EBIT -43.47
ICPT's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ICPT: -43.47 )
Ranked among companies with meaningful EV-to-EBIT only.
ICPT' s 10-Year EV-to-EBIT Range
Min: -215.1  Med: -36.30 Max: -15.7
Current: -43.47
-215.1
-15.7
Current Ratio 22.61
ICPT's Current Ratio is ranked higher than
92% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ICPT: 22.61 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s 10-Year Current Ratio Range
Min: 0.48  Med: 16.13 Max: 25.72
Current: 22.61
0.48
25.72
Quick Ratio 22.61
ICPT's Quick Ratio is ranked higher than
92% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ICPT: 22.61 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s 10-Year Quick Ratio Range
Min: 0.48  Med: 16.13 Max: 25.72
Current: 22.61
0.48
25.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.67
ICPT's Price/Net Cash is ranked lower than
72% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ICPT: 15.67 )
Ranked among companies with meaningful Price/Net Cash only.
ICPT' s 10-Year Price/Net Cash Range
Min: 7.4  Med: 15.43 Max: 20.35
Current: 15.67
7.4
20.35
Price/Net Current Asset Value 15.33
ICPT's Price/Net Current Asset Value is ranked lower than
74% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ICPT: 15.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICPT' s 10-Year Price/Net Current Asset Value Range
Min: 7.3  Med: 15.01 Max: 19.86
Current: 15.33
7.3
19.86
Price/Tangible Book 14.89
ICPT's Price/Tangible Book is ranked lower than
84% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ICPT: 14.89 )
Ranked among companies with meaningful Price/Tangible Book only.
ICPT' s 10-Year Price/Tangible Book Range
Min: 7.27  Med: 14.63 Max: 19.34
Current: 14.89
7.27
19.34
Price/Median PS Value 1.02
ICPT's Price/Median PS Value is ranked higher than
54% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ICPT: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
ICPT' s 10-Year Price/Median PS Value Range
Min: 0.03  Med: 0.72 Max: 2.1
Current: 1.02
0.03
2.1
Earnings Yield (Greenblatt) (%) -2.31
ICPT's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ICPT: -2.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.1  Med: 0.00 Max: 0
Current: -2.31
-3.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming... Jul 29 2015
Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming... Jul 29 2015
Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S. Jul 21 2015
Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S. Jul 21 2015
Gilead's next target? Jul 09 2015
Intercept Pharmaceuticals Makes a Breakthrough Jul 07 2015
DALCOMP NEGOTIATED CALENDAR Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015
Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog Jun 30 2015
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jun 30 2015
Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of... Jun 29 2015
Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of... Jun 29 2015
Intercept Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President... Jun 22 2015
Intercept Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President... Jun 22 2015
Edited Transcript of ICPT earnings conference call or presentation 11-May-15 1:45pm GMT Jun 17 2015
LLTP Shares Attractive On Rolling NDA Submission - 300 Percent in Potential Upside Jun 17 2015
4 Big Biotech Companies to Sell Now May 26 2015
What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds May 23 2015
Will This Drug Beat Gilead to Market in NASH? May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK